Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOS-AMI trial of self-administered subcutaneous selatogrel after recent acute myocardial infarction
CTR20230880Phase 3Active
- Sponsor
- Idorsia
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of selatogrel in myocardial infarction (MI), sponsored by Idorsia. Started Mar 2024; status: active.
02
Drugs
selatogrel
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on CTR20230880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230880.